Literature DB >> 6391407

Theophylline in stable chronic airflow obstruction. A reappraisal.

W L Dull, M R Alexander.   

Abstract

Theophylline is commonly recommended for patients who have stable chronic airflow obstruction (CAO). Recent evidence confirms that serum theophylline concentrations between 10 and 20 mg/L may increase forced expiratory volume in 1 s (FEV1) and forced vital capacity in these patients. Exercise tolerance, however, and the classic respiratory symptoms of wheezing, breathlessness, cough, and sense of well-being do not improve. A reappraisal of the role of this medication in patients with stable CAO is therefore necessary; we recommend not prescribing this medication for all patients. Instead, the response of FEV1 after isoproterenol inhalation (0.15 mg) should be monitored. This simple test has good efficacy for predicting the response to oral theophylline therapy and could diminish the cost and unnecessary side effects of theophylline while benefiting those who will respond.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391407

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  2 in total

1.  Bronchodilator treatment for partially reversible chronic obstructive airways disease.

Authors:  M K Tandon; S G Kailis
Journal:  Thorax       Date:  1991-04       Impact factor: 9.139

2.  Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline.

Authors:  P E Brander; T Salmi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.